Sugi Predict

Sugi Predict / Compounds / SCHEMBL114416

SCHEMBL114416

SCHEMBL114416

Nc1cc(N2CCOCC2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LGMN Q99538 3/20 0.53
▸ CDK1 P06493 1/20 0.51
▸ CDK2 P24941 1/20 0.51
▸ NPC1 O15118 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ ALOX15 P16050 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CHEK1 O14757 4/20 0.47
▸ DHFR P00374 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ JAK2 O60674 1/20 0.45
▸ PIK3CA P42336 2/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ PIK3R1 P27986 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ MAPK10 P53779 1/20 0.43
▸ AGXT P21549 1/20 0.43
▸ PRKDC P78527 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30321663 1.00 LGMN (0.53) LGMNCDK1CDK2NPC1TP53
Hydrochloric Acid SCHEMBL4301140 0.98 LGMN (0.51) LGMNCDK1CDK2NPC1TP53
SCHEMBL1097561 0.83 CHKA (0.52) NPC1TP53MAPTALOX15RAB9A
SCHEMBL16212228 0.83 HRH4 (0.47) NPC1TP53MAPTALOX15RAB9A
SCHEMBL5847761 0.81 HRH4 (0.54) NPC1TP53MAPTALOX15RAB9A
SCHEMBL6262576 0.81 HRH4 (0.54) NPC1TP53MAPTALOX15RAB9A
SCHEMBL27936855 0.80 LRRK2 (0.59) LGMNCDK1CDK2SMN1; SMN2LMNA
SCHEMBL10767289 0.79 HRH4 (0.39) CDK1CDK2MAPTSMN1; SMN2LMNA
SCHEMBL7015551 0.79 LGMN (0.53) LGMNCDK1CDK2NPC1MAPT
SCHEMBL5848445 0.79 LGMN (0.54) LGMNCDK2MAPTALOX15CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116789643-A 2-aminopyrimidine compound and preparation method and application thereof 海南医学院 2023-09-22 — — CN claimed
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. 2025-02-20 — — US disclosed
EP-3891167-B1 ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1 Organon R&D Finland Oy (FI) 2024-11-13 — — EP disclosed
CN-116789643-A 2-aminopyrimidine compound and preparation method and application thereof 海南医学院 2023-09-22 — — CN disclosed
WO-2023129933-A2 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
WO-2023129933-A2 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS 858 THERAPEUTICS, INC. (US) 2023-07-06 — — WO disclosed
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 — — US disclosed
US-20230203003-A1 Notch Inhibitors and Uses Thereof STEMSYNERGY THERAPEUTICS, INC. 2023-06-29 — — US disclosed
EP-4153576-A1 NOTCH INHIBITORS AND USES THEREOF StemSynergy Therapeutics, Inc. (US) 2023-03-29 — — EP disclosed
CN-115836056-A NOTCH inhibitors and uses thereof STEMSYNERGY疗法有限责任公司 2023-03-21 — — CN disclosed
CN-101072758-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-11-14 — — CN disclosed
EP-1802608-A1 QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER AstraZeneca AB (SE) 2007-07-04 — — EP disclosed
EP-1802591-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2007-07-04 — — EP disclosed
US-7115596-B2 Thiazole compounds as integrin receptor antagonists derivatives PHARMACIA CORPORATION (US) 2006-10-03 — — US disclosed
WO-2006040520-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2006040526-A1 QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
EP-1572690-A1 THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES Pharmacia Corporation (US) 2005-09-14 — — EP disclosed
US-20050004189-A1 Thiazole compounds as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2005-01-06 — — US disclosed
WO-2004058760-A1 THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES PHARMACIA CORPORATION (US) 2004-07-15 — — WO disclosed
WO-2004058760-A1 THIAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES PHARMACIA CORPORATION (US) 2004-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203003-A1 Notch Inhibitors and Uses Thereof NOTCH1, NOTCH2, NOTCH4 LGMN 667/4885CDK1 2363/4885CDK2 2325/4885
US-20050004189-A1 Thiazole compounds as integrin receptor antagonists derivatives ITGA5, ITGB5, ITGAL LGMN 3968/4885CDK1 2586/4885CDK2 1726/4885
US-20250059207-A1 6,6-FUSED HETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS METTL3, METTL16, TPMT LGMN 1916/4885CDK1 2755/4885CDK2 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.